IMPERIAL OIL LTD — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IMPERIAL OIL LTD filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 47.08B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 51.53B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 50.97B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 59.67B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 37.59B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 22.39B | Feb 22, 2023 |
| FY2012 | Dec 31, 2012 | 4.36B | Feb 27, 2013 |
| FY2012 | Dec 31, 2011 | 4.18B | Feb 27, 2013 |
| FY2012 | Dec 31, 2010 | 3.65B | Feb 27, 2013 |
| FY2011 | Dec 31, 2009 | 3.46B | Feb 27, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.27B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 4.79B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 4.89B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 7.34B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 2.48B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (1.86B) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 2.20B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 2.31B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 490.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 2.17B | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 134.00M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 118.00M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 84.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 74.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 89.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 105.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 133.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 110.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 111.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 152.00M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.39B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 945.00M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 857.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 882.00M | Feb 19, 2025 |
| FY2015 | Dec 31, 2015 | 1.12B | Feb 24, 2016 |
| FY2015 | Dec 31, 2014 | 1.08B | Feb 24, 2016 |
| FY2015 | Dec 31, 2013 | 1.08B | Feb 24, 2016 |
| FY2014 | Dec 31, 2012 | 1.08B | Feb 25, 2015 |
| FY2013 | Dec 31, 2011 | 1.17B | Feb 26, 2014 |
| FY2012 | Dec 31, 2010 | 1.07B | Feb 27, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.71B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 5.98B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 3.73B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 10.48B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 5.48B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 798.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 4.43B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 3.92B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 2.76B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 2.02B | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.31B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 42.94B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 41.20B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 43.52B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 40.78B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 38.03B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 42.19B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 41.46B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 41.60B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 41.65B | Feb 27, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.06B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 19.47B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 18.98B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 21.11B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 19.05B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 16.61B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 17.91B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 16.97B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 17.17B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 16.63B | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22.25B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 23.47B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 22.22B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 22.41B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 21.74B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 21.42B | Feb 22, 2023 |
| FY2010 | Dec 31, 2010 | 11.18B | Feb 25, 2011 |
| FY2010 | Dec 31, 2009 | 9.44B | Feb 25, 2011 |
| FY2010 | Dec 31, 2008 | 9.07B | Feb 25, 2011 |
| FY2009 | Dec 31, 2007 | 7.92B | Feb 26, 2010 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 166.00M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 166.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 166.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 166.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 166.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 166.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 186.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 186.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 186.00M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 186.00M | Mar 1, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21.37B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 22.75B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 21.91B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 21.85B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 21.66B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 22.05B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 24.81B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 24.56B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 24.71B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 25.35B | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.14B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 979.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 864.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 3.75B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 2.15B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 771.00M | Feb 23, 2022 |
| FY2021 | Dec 31, 2019 | 1.72B | Feb 23, 2022 |
| FY2021 | Dec 31, 2018 | 988.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2017 | 1.20B | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | 391.00M | Feb 26, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 11 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 2 | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 2 | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 27, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 11 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 2 | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 2 | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 27, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 483.59M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 509.05M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 536.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 584.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 678.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 734.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 744.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 783.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 831.00M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | 847.60M | Feb 27, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.40B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 1.24B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 1.10B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 851.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 706.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 649.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 631.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 572.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 524.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 492.00M | Feb 27, 2019 |